Inactive Instrument

Highlights Centrexion Therapeutics Corporation

Equities

CNTX

US15643W1009

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

CONTEXT THERAPEUTICS INC. Management's Discussion and Analysis of Financial Condition and Results of Operations (form 10-Q)	22-05-11	AQ
Earnings Flash (CNTX) CONTEXT THERAPEUTICS Posts Q1 Loss $-0.22	22-05-11	MT
CONTEXT THERAPEUTICS INC. Management's Discussion and Analysis of Financial Condition and Results of Operations (form 10-K)	22-03-23	AQ
Context Therapeutics® Reports Full Year 2021 Operating and Financial Results	22-03-23	AQ
Health Care Stocks Staying On Positive Ground in Late Trade	21-12-10	MT
Health Care Stocks Hanging On For Slim Gains	21-12-10	MT
Context Therapeutics Q3 Net Loss Widens	21-12-02	MT
MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS	21-12-02	AQ
Earnings Flash (CNTX) CONTEXT THERAPEUTICS Reports Q3 Loss $-4.00	21-12-02	MT
Context Therapeutics® Reports Third Quarter 2021 Operating and Financial Results	21-12-02	AQ
CONTEXT THERAPEUTICS INC. : Change in Directors or Principal Officers, Amendments to Articles of Inc. or Bylaws; Change in Fiscal Year, Other Events, Financial Statements and Exhibits (form 8-K)	21-10-22	AQ
Centrexion Therapeutics : Context Therapeutics Closes $28.8 Million IPO	21-10-22	MT
Centrexion Therapeutics : Context Therapeutics® Announces Closing of Initial Public Offering, Including Full Exercise of Underwriter’s Over-allotment Option	21-10-22	AQ
Centrexion Therapeutics : Context Therapeutics Debuts On Nasdaq	21-10-20	MT
Centrexion Therapeutics : Context Therapeutics Prices IPO of 5 Million Common Shares at $5 Apiece	21-10-20	MT
Centrexion Therapeutics Corporation has withdrawn its IPO.	20-10-23	CI
Centrexion Corp Reports Earnings Results for the Half Year Ended June 30, 2019	19-09-18	CI
Centrexion Therapeutics Announces Completion of Patient Enrollment in VICTORY-3 Phase 3 Open-Label Clinical Trial of CNTX-4975 in Patients with Moderate-to-Severe Osteoarthritis Knee Pain	19-09-17	CI
Centrexion Therapeutics Announces CNTX-4975, CNTX-0290 and CNTX-6970 Data Presentations at PAINWeek 2019 National Conference	19-09-04	CI
Centrexion Therapeutics to Present New Positive Clinical Trial Results on Streamlined CNTX-4975 Administration Techniques	19-07-18	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights Centrexion Therapeutics Corporation

Equities

CNTX

US15643W1009

Highlights

Filters